BiotechTube

AZD5213

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Brain Distribution of [11C]AZ12807110 and AZD5213

Conditions

Brain Distribution of [11C]AZ12807110 and AZD5213

Trial Timeline

Nov 1, 2010 → Jun 1, 2011

NCT ID
NCT01194986

About AZD5213

AZD5213 is a phase 1 stage product being developed by AstraZeneca for Brain Distribution of [11C]AZ12807110 and AZD5213. The current trial status is completed. This product is registered under clinical trial identifier NCT01194986. Target conditions include Brain Distribution of [11C]AZ12807110 and AZD5213.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01194986Phase 1Completed

Competing Products

20 competing products in Brain Distribution of [11C]AZ12807110 and AZD5213

See all competitors
ProductCompanyStageHype Score
Abemaciclib + Endocrine therapyEli LillyPhase 1/2
41
Duloxetine + Sugar pillEli LillyPhase 2
52
Neurosteroid enantiomerOragenicsPhase 2
44
Patritumab deruxtecanDaiichi SankyoPhase 2
52
filgrastim + exatecan mesylateDaiichi SankyoPhase 1
33
Eribulin MesylateEisaiPhase 1
33
Pembrolizumab + LenvatinibEisaiPhase 2
52
Palonosetron (Aloxi) and DexamethasoneEisaiPhase 2
52
GLIADELEisaiPhase 2
52
Nivolumab + TemozolomideOno PharmaceuticalPhase 3
77
Nivolumab + TemozolomideOno PharmaceuticalPhase 3
77
Prexasertib + Cyclophosphamide + Gemcitabine + filgrastim + peg-filgrastimEli LillyPhase 1
33
abemaciclib + abemaciclibEli LillyPhase 2
52
JNJ-17299425Johnson & JohnsonPhase 2
52
ABT-888AbbViePhase 1
33
Veliparib + PlaceboAbbViePhase 2
52
Iressa (Gefitinib)AstraZenecaPhase 2
52
Trastuzumab deruxtecanAstraZenecaPhase 2
52
ExenatideAstraZenecaApproved
85
VorinostatMerckPhase 1
33

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85